Noted in Passing

The first day after Lipitor’s patent expired and the news is filled with talk about the measures Pfizer are taking to protect their market share against the generic competition. I had predicted that Big Pharma would be more proactive in promoting their newly off-patent medicines and, while Lipitor may be a special case as the biggest seller, I am sure other companies are watching the outcome with interest, to see how successful they might be in retaining some of that revenue.

Talking of things I wrote about before, I saw that Astrazeneca are putting more funds into their VC arm, MedImmune Ventures. The senior managing director, Ron Laufer, noted that “there is a growing role for corporate VC funds”. All the Big Pharma have these investment vehicles and they are going to be increasingly important with less internal R&D going on.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.